Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $87.10, for a total value of $435,500.00. Following the sale, the senior vice president now owns 34,237 shares of the company’s stock, valued at approximately $2,982,042.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Puma Biotechnology Inc (NYSE PBYI) traded down 3.2104% during mid-day trading on Monday, hitting $86.6751. The company had a trading volume of 484,431 shares. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $94.70. The firm’s market cap is $3.20 billion. The firm’s 50 day moving average is $70.29 and its 200-day moving average is $44.73.
Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. On average, equities analysts expect that Puma Biotechnology Inc will post ($8.44) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce Sells 5,000 Shares of Stock” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/07/17/puma-biotechnology-inc-nysepbyi-svp-richard-paul-bryce-sells-5000-shares-of-stock.html.
A number of equities research analysts have weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $105.00 price objective on shares of Puma Biotechnology in a research note on Monday, June 5th. Zacks Investment Research lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Credit Suisse Group lifted their target price on Puma Biotechnology from $58.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 25th. Royal Bank Of Canada set a $40.00 target price on Puma Biotechnology and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $88.00 target price on shares of Puma Biotechnology in a research report on Monday, May 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $89.75.
Several large investors have recently added to or reduced their stakes in the stock. Creative Planning increased its position in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 1,099 shares during the last quarter. Bank of Montreal Can increased its position in shares of Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 97 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Puma Biotechnology during the second quarter valued at approximately $227,000. Credit Suisse AG increased its position in shares of Puma Biotechnology by 97.9% in the first quarter. Credit Suisse AG now owns 82,644 shares of the biopharmaceutical company’s stock valued at $3,075,000 after buying an additional 40,890 shares during the last quarter. Finally, Redmile Group LLC increased its position in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock valued at $64,185,000 after buying an additional 435,274 shares during the last quarter. Institutional investors own 80.98% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.